Carboplatin-gemcitabine Versus Cisplatin- Gemcitabine as Neoadjuvant Chemotherapy for Treatment of Muscle Invasive Urinary Bladder Cancer
Condition(s):Urinary Bladder CancerLast Updated:April 25, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Urinary Bladder CancerLast Updated:April 25, 2023Recruiting
Condition(s):Patients With High-risk MIBCLast Updated:November 13, 2023Recruiting
Condition(s):Bladder CancerLast Updated:November 14, 2023Recruiting
Condition(s):Bladder CancerLast Updated:September 28, 2023Recruiting
Condition(s):Bladder Carcinoma in Situ (CIS)Last Updated:January 10, 2024Recruiting
Condition(s):Bladder CancerLast Updated:March 12, 2024Recruiting
Condition(s):Bladder CancerLast Updated:August 16, 2022Recruiting
Condition(s):Urothelial Carcinoma; Bladder CancerLast Updated:October 5, 2023Recruiting
Condition(s):Transitional Cell Carcinoma; Bladder CancerLast Updated:May 7, 2021Not yet recruiting
Condition(s):Complications, PostoperativeLast Updated:April 28, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.